Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock Price
KYTXStock
$8.37+126.22%52W
Market Cap$517.63M
P/E—
PEG Ratio—
Div yield—
Beta2.03
KYTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.65%
Price vs S&P 500 (4W)9.91%
VGM Score66.85
KYTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.68 | -$0.63 | +7.28%(+$0.05) | |
| Q4 2025 | -$0.86 | -$0.80 | +6.80%(+$0.06) | |
| Q3 2025 | -$0.97 | -$0.85 | +12.47%(+$0.12) | |
| Q2 2025 | -$1.04 | -$0.97 | +7.15%(+$0.07) |
KYTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KYTXKyverna Therapeutics, Inc. Common Stock | — | — | B | $8.37 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. Its pipeline includes KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version designed for multiple autoimmune indications.